ISPC vs LIN · rev $9.3M vs P/E 34, rev $33.99B
iSpecimen Inc (ISPC) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
iSpecimen Inc (ISPC) is a diagnostics & research company listed on US.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported ISPC revenue for 2024-12-31 was $9.3M. Net income was -$12.5M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ISPC currently screens at market cap $4.4M.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
ISPC currently screens at market cap $4.4M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the ISPC and LIN stock pages for the full models.
Not investment advice.